Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus
Top Cited Papers
Open Access
- 1 March 2019
- journal article
- research article
- Published by Elsevier BV in Cell
- Vol. 176 (6), 1420-1431.e17
- https://doi.org/10.1016/j.cell.2019.01.046
Abstract
No abstract availableKeywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1120319, OPP1126258, OPP1162875)
- Washington
- Howard Hughes Medical Institute
- Netherlands Organization for Scientific Research (Rubicon 019.2015.2.310.006)
- European Molecular Biology Organisation (ALTF 933-2015)
- Swedish Research Council (2015-02608)
- Karolinska Institutet
- NIAID (HHSN272201700059C)
- NIGMS (R01GM120553)
- Pew Biomedical
- Burroughs Wellcome Fund
This publication has 67 references indexed in Scilit:
- Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor AntibodiesImmunity, 2018
- A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing ageVaccine, 2017
- Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2eLife, 2016
- The coming of age of de novo protein designNature, 2016
- Self-assembling protein nanoparticles in the design of vaccinesComputational and Structural Biotechnology Journal, 2016
- Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protectionNature Medicine, 2015
- Analysis of Overlapped and Noisy Hydrogen/Deuterium Exchange Mass SpectraJournal of the American Society for Mass Spectrometry, 2013
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in IndonesiaVaccine, 2012
- Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trialVaccine, 2011